Strides Shasun is currently trading at Rs. 1093.00, up by 12.50 points or 1.16% from its previous closing of Rs. 1080.50 on the BSE.
The scrip opened at Rs. 1085.60 and has touched a high and low of Rs. 1100.00 and Rs. 1077.00 respectively. So far 8,550 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1400.00 on 10-Dec-2015 and a 52 week low of Rs. 848.00 on 29-Feb-2016.
Last one week high and low of the scrip stood at Rs. 1109.40 and Rs. 1000.00 respectively. The current market cap of the company is Rs. 9,759.00 crore.
The promoters holding in the company stood at 31.14%, while Institutions and Non-Institutions held 47.91% and 20.95% respectively.
Strides Shasun’s wholly owned subsidiary Strides Arcolab International, UK has entered into an agreement with Moberg Pharma, Sweden to acquire the 'PediaCare' brand for a total consideration of $5 million plus inventory value at closing.
PediaCare is an established paediatric cough, cold and allergy brand with annual sales of approximately $6 million. PediaCare will form an important part of Strides expanding consumer health care portfolio and brings with it expertise in the paediatric segment as well as a strong brand name with global potential.
Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
